1:34AM Santarus sees FY12 and FY13 revs above consensus; co also announced it received FDA approval of UCERIS (SNTS) 11.28 : Co issues upside guidance for FY12 (Dec), sees FY12 (Dec) revs of ~$210 mln vs. $209.33 mln Capital IQ Consensus Estimate. Co issues upside guidance for FY13 (Dec), sees FY13 (Dec) revs of ~$320-325 mln vs. $301.25 mln Capital IQ Consensus Estimate. Financial Outlook for 2012 and 2013 For the full year in 2012, co expects to meet or exceed the financial guidance provided on its November 7, 2012 third quarter financial results conference call of:
Net income of ~$12-14 mln, which includes the impact of the ~$4 mln success-based regulatory milestone expense in the first quarter of 2012 related to UCERIS and a $10 mln expense for the success-based clinical milestone for RUCONEST in the fourth quarter.
Adjusted EBITDA of ~$29-32 mln.
Co is introducing its financial outlook for full year 2013 as follows:
Net income of approximately $50-54 mln.
Adjusted EBITDA of ~$73-79 mln.
*Co also announced it received FDA approval of UCERIS for the induction of remission in patients with active, mild to moderate ulcerative colitis.
1:30AM Santarus receives FDA approval of UCERIS for the induction of remission in patients with active, mild to moderate ulcerative colitis (SNTS) 11.28 : Co announces the FDA has approved UCERIS extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis. The co expects to commence the commercial launch of UCERIS in March 2013.